Health Press Releases & Articles 661 - 665 of 771


Nucletron Releases Comprehensive Film-and Volume-based Planning System For Wide Variety Of Brachy So starstarstarstarstar   15th May 2009 - Views: 901 Nucletron Releases Comprehensive Film-and Volume-based Planning System For Wide Variety Of Brachy So Nucletron, a knowledge-based leader in radiation oncology, today announced a new release of Oncentra(R) Brachy, a comprehensive film- and volume-based treatment planning system to optimize cancer treatment planning for brachytherapy. Oncentra Brachy, the world's first fully DICOM-compatible treatment planning system, is a user-friendly Windows-based planning system that features state-of-the-art optimization algorithms to ensure efficient treatment.

New Breast Cancer Treatment Improves Survival Time starstarstarstarstar   14th May 2009 - Views: 935 New Breast Cancer Treatment Improves Survival Time A new treatment option for Australian women with metastatic breast cancer which improves survival time and reduces the side effects of common chemotherapy treatment is set to be widely available to Australian women now that is has been listed on the Pharmaceutical Benefits Scheme.

Indigenous Child Health Measures Welcomed starstarstarstarstar   13th May 2009 - Views: 852 Indigenous Child Health Measures Welcomed “A new long overdue program aimed at improving Indigenous rural and regional dental health is also welcomed,” said Mick Gooda.

Garvan St Vincent's Campus Cancer Centre Welcomes $70 Million From Federal Govt starstarstarstarstar   13th May 2009 - Views: 866 Garvan St Vincent's Campus Cancer Centre Welcomes $70 Million From Federal Govt The Federal Government has announced a $70m funding package to enable the development of the Garvan St Vincent’s Campus Cancer Centre (GSVCCC). The Centre will integrate the Garvan Institute’s internationally acclaimed cancer research with the best practice clinical care of St Vincent’s.

Nerviano Medical Sciences Receives Approval From The Fda To Enter Phase I Clinical Trials For Their starstarstarstarstar   13th May 2009 - Views: 836 Nerviano Medical Sciences Receives Approval From The Fda To Enter Phase I Clinical Trials For Their The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells.

news articles logo NEWS ARTICLES
Contact News Articles